← board
ICCC
distress 0/10 · well-funded / low risk$11.00-1%today-6% from 52w high
Revenue
$10M
Liquidity
$7M
Runway
—
Shares 1y
0%
Price & events
+67.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
-1.2%
1W
+11.4%
1M
+37.5%
3M
+75.7%
6M
+58.3%
1Y
+165.1%
2Y
+7.4%
5Y
+80.3%
All
Overview
- Market Cap
- $99.51M
- Enterprise Value
- $99.78M
- Volume
- 456
- 52 Week Range
- $4.56 – $11.72
- Total Shares
- 9.05M
- Float Shares
- 6.00M
- Short %
- 0.25%
- % Held by Insiders
- 32.13%
- % Held by Institutions
- 21.62%
- RVOL
- 0.01x
- Beta
- 0.57
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-12-24trial discontinuedRe-Tain · ImmuCell pauses further investment in Re-TainSEC 8-K
- 2025-12-24refuse to fileRe-Tain · FDA Incomplete Letter regarding contract manufacturer deficiencies leading to pause in investmentSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-10ImmuCell Corporation Files Form 8-K: Key Financial Data and Company Information for July 2026 - Minichart
- 2026-07-09ImmuCell reports Q2 product sales up 11.5% to $7.2M; six‑month sales up 20.9% to $17.5M - TradingView
- 2026-07-09ImmuCell (ICCC) Q2 2026 sales hit $7.2M as six-month revenue climbs 20.9% - Stock Titan
- 2026-07-09ImmuCell sales jump 12% in Q2 as U.S. demand lifts calf products - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.